HPV-associated genital diseases: current diagnosis and treatment options

Optimizing the management of patients with HPV-associated cervical diseases remains a priority for the modern studies on this issue. The human papillomavirus is divided into two types: high-risk and low-risk types according to its malignant potential to cause cervical cancer and some other oncological diseases. Human papillomavirus can clear spontaneously in 85-90% cases, but the risk of cervical intraepithelial neoplasia and invasive cervical cancer is quite high in persistent high-risk oncogenic infection. The virus presence in the body tissues cannot be considered as a marker for progression or regression of the pathological process in the strict sense, even though cervical intraepithelial neoplasia and cervical cancer develop in HPV-positive patients in the vast majority of cases. These studies are aimed at searching for the new and improving existing methods for early diagnosis of precancerous diseases and cervical cancer. The development of the HPV-associated pathological process is known to be dependent on the human immune system status. The virus provokes a cellular immune response, which is expressed as changes in interferon status, cytotoxic activity of natural killer cells, methylation processes, etc. The use of a holistic approach to treatment, a comdoibination of traditional therapy, antigen-specific vaccination and administration of immunomodulating agents seems relevant for patients with persistent high-risk oncogenic papilloma virus, as well as precancerous diseases and cervical cancer. The use of immunomodulators in the complex treatment of virus-associated diseases contributes to relief of symptoms and reduction of the recurrence rate.

1. Zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology. 2009; 384(2):260–265. doi: 10.1016/j.virol.2008.11.046.

2. Galloway D.A., Laimins L.A. Human papillomaviruses: shared and distinct pathways for pathogenesis. Current Opinion in Virology. 2005;14:87–92. doi: 10.1016/j.coviro.2015.09.001.

3. Bravo I.G., Felez-Sanchez M. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health. 2015;2015(1)1:32–51. doi: 10.1093/emph/eov003.

4. Doorbar J., Quint W., Banks L., Bravo I.G., Stoler M., Broker T.R., Stanley M.A. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–70. doi: 10.1016/j.vaccine.2012.06.083.

5. Christensen N.D. HPV disease transmission protection and control. Microb Cell. 2016;3(9):476–490. doi: 10.15698/mic2016.09.530.

6. Van Doorslaer K., Bernard H.U., Chen Z., de Villiers E.M., zur Hausen H., Burk R.D.Papillomaviruses: evolution, Linnaean taxonomy and current nomenclature. Trends Microbiol. 2011;19(2):49–50. doi: 10.1016/j.tim.2010.11.004.

7. Darrell H., Branch C. Bioinformatics and Computational Biosciences Branch. Papillomavirus Episteme. National Institute of Allergy and Infectious Diseases; 2019. Available at: https://www.niaid.nih.gov/research/pave.

8. Bzhalava D., Muhr L.S., Lagheden C., Ekstrom J., Forslund O., Dillner J., Hultin E. Deep sequencing extends the diversity of human papillomaviruses in human skin. Sci Rep. 2014;4:5807. doi: 10.1038/srep05807.

9. Nagai Y. Persistence of human papillomavirus infection after therapeutic conization for CIN III: is it an alarm for disease recurrence? Gynecol Oncol. 2000;79(2):294–299. doi: 10.1006/gyno.2000.5952.

10. Prilepskaya V.N., Dovletkhanova E.R. Features of diagnosis, clinical manifestation and treatment of HPV-associated diseases. Ginekologiya = Gynecology. 2013;(5):7–12. (In Russ.) Available at: http://www.fesmu.ru/elib/Article.aspx?id=289240.

11. Kiselev V.I., Apolikhina I.A., Muyzhnek E.L., Denisova E.D. Pathogenetic approaches to the treatment of HPV-associated cervical diseases. In the book: Prilepskaya V.N. (ed.). Patologiya sheyki matki i genitalnye infektsii = Pathology of cervix and genital infections. Moscow: MEDpress-inform Publisher; 2008, p. 87–93, (In Russ.)

12. DiMaio D., Petti L.M. The E5 proteins. Virology. 2013;445(1–2):99–114. doi: 10.1016/j.virol.2013.05.006.

13. Santoso J.T., Long M., Crigger M. et al. Anal intraepithelial neoplasia in women with genital intraepithelial neoplasia. Obstet Gynecol. 2010;116(3):578–582. doi: 10.1097/AOG.0b013e3181ea1834.

14. Lobato S., Tafuri A., Fernandes P.A., Caliari M.V., Silva M.X., Xavier M.A., Vago A.R. Minichromosome maintenance 7 protein is a reliable biological marker for human cervical progressive disease. J Gynecol Oncol. 2012;23(1):11–15. doi: 10.3802/jgo.2012.23.1.11.

15. Baranov A.A., Namazova-Baranova L.S., Tatochenko V.K., Vishneva E.A., Fedoseenko M.V., Selimzyanov L.R. et al. Vaccination against diseases caused by human papillomavirus. Clinical guidelines. Moscow; 2017. 25 p. (In Russ.) Available at: http://www.pediatr-russia.ru/sites/default/files/file/kr_vacpap.pdf.

16. Bruni L., Albero G., Serrano B., Mena M., Gomez D., Munoz J., Bosch F.X., de Sanjose S., ICO/IARC. Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related. Diseases in the World. Summary Report 17 June 2019. Available at: https://hpvcentre.net/statistics/reports/XWX.pdf.

17. Egawa N., Egawa K., Griffin H., Doorbar J. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses. 2015;7(7):3863–3890. doi: 10.3390/v7072802.

18. Doorbar J., Egawa N., Griffin H., Kranjec C., Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23 doi: 10.1002/rmv.1822.

19. Nazarova N.M., Bestayeva N.V., Prilepskaya V.N., Trofimov D.Yu., Kostava M.N. The diagnosis and treatment of papillomavirus infection-associated diseases: New directions and controversial issues. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2012;(5):10–16. (In Russ.) Available at: https://aig-journal.ru/articles/Novye-napravleniya-i-diskussionnyevoprosy-diagnostiki-i-lecheniya-zabolevanii-associirovannyhspapillomavirusnoi-infekciei.html

20. Ataullakhanov R.I., Pichugin A.V., Shishkova N.M., Masternak Т.В., Malkina E. Yu., Ulyanova L.I., Stetsenko O.N. Cell mechanisms of the immunomodulating action produced by drug «Immunomax». Immunologiya = Immunology. 2005;26(2):111–120. (In Russ.) Available at: https://elibrary.ru/item.asp?id=9134114

21. Bibicheva Т.V. Clinical efficiency of immunomax in papillomavirus infection therapy. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya: Meditsina. Farmatsiya = Belgorod State University Scientific Bulletin. Medicine. Pharmacy series. 2012;(4–1):42–45. (In Russ.) Available at: https://elibrary.ru/item.asp?id=19433989

22. Sukhikh G.T., Prilepskaya V.N. (eds.). Cervical cancer prevention: guidelines for physicians. M.: MEDpress-inform; 2012, рp. 79-86. (In Russ.) Available at: https://elibrary.ru/item.asp?id=19564400.

23. Zikeeva A.A., Bibicheva T.V., Silina L.V. Features of systemic immunity indicators trend in patients with isolated and urogenital trichomoniasis combined HPV-infections against the background of various therapy methods. Vestnik poslediplomnogo meditsinskogo obrazovaniya = Journal of postgraduate medical education. 2011;(4):11–14. (In Russ.) Available at: http://vpmo.info/arhive/n4-2_2011.pdf.